RxDoctor Payments Data

Carolyn Pignataro, APRN

Psychiatric/Mental Health · Cheyenne, WYNPI 1780227991

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alkermes, Inc. at 38.4% of the total.

$1,521in general payments, 2019–2025

Across 42 payments — averaging $36.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$585
  • Neurocrine Biosciences, Inc.$375
  • Teva Pharmaceuticals USA, Inc.$198
  • AbbVie$183
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$119
  • Lundbeck LLC$27
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$1,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,521 in reported general payments places this provider in the 80th percentile of 76 psychiatric/mental health providers in Wyoming.

See all psychiatric/mental health providers in Wyoming

Medicare billing

Part B allowed, 2024
$26,919
Medicare patients
86
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FanaptIloperidone24$63,063
RexultiBrexpiprazole34$51,733
VraylarCariprazine Hcl23$35,631
CaplytaLumateperone Tosylate20$32,921
AristadaAripiprazole Lauroxil16$29,442
Aripiprazole174$9,431
Clozapine62$8,462
VyvanseLisdexamfetamine Dimesylate17$6,822
QuviviqDaridorexant Hcl13$6,649
BelsomraSuvorexant16$6,370
Lurasidone Hcl96$4,954
VascepaIcosapent Ethyl15$4,787
Quetiapine Fumarate197$4,177
Olanzapine189$3,912
Trazodone Hcl264$3,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$183$35,63123 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$119$32,92120 claims
Alkermes, Inc.Aristada$585$29,44216 claims
Teva Pharmaceuticals USA, Inc.Loxapine$198$1,94438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 76 psychiatric/mental health providers in Wyoming.

Other psychiatric/mental health in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →